How (AHCO) Movements Inform Risk Allocation Models
Adapthealth Corp. (NASDAQ: AHCO) is exhibiting weak near-term sentiment within a broader long-term weak bias, though mid-term strength is noted. AI models have generated three distinct trading strategies—Position Trading (long), Momentum Breakout (breakout), and Risk Hedging (short)—each with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 111.0:1 risk-reward setup targeting a 32.2% gain versus 0.3% risk.
AdaptHealth Corp. (AHCO) Stock forecasts
This article provides a brief overview of AdaptHealth Corp. (AHCO) and its stock forecast, based on an Argus quantitative report dated November 18, 2026. AdaptHealth Corp. is described as a provider of patient-centered healthcare-at-home solutions. The report includes a current price of $7.25 and offers a price target.
AdaptHealth (AHCO) - Teleconferência de Resultados do 3T26: Margem Capitada Melhora, Guidance Elevado
AdaptHealth (AHCO) reportou uma receita líquida de US$ 745,6 milhões no 3T26, um aumento de 10,9% ano a ano, impulsionada por um crescimento orgânico de 12,8%. A margem EBITDA ajustada para o maior contrato capitado melhorou de -4% no 2T26 para 10% no 3T26, com uma taxa de saída de 14% em setembro, e a empresa visa uma margem de pelo menos 20% até o 4T27. A AdaptHealth elevou sua projeção de receita líquida para 2026 para US$ 2,88 bilhões–US$ 2,90 bilhões e a projeção de EBITDA ajustado para US$ 510 milhões–US$ 525 milhões, enquanto reduziu a projeção de fluxo de caixa livre devido a pagamentos antecipados a fornecedores.
Has AdaptHealth (AHCO) Fallen Far Enough To Look Like A Bargain?
AdaptHealth (AHCO) has seen a significant share price drop of 65.8% over the past five years, prompting questions about its current valuation. The company's P/S ratio of 0.3x is substantially lower than industry averages, suggesting it may be undervalued. While some analysts are bullish, predicting it could be 21% undervalued, investors need to assess if the quality and predictability of its revenue stream justify the current market discount.
Form 144 ADAPTHEALTH CORP. For: 12 November By Investing.com
This article from Investing.com announces the filing of Form 144 for ADAPTHEALTH CORP. on November 12. Form 144 indicates an intent to sell restricted securities. The article provides the title of the filing and mentions the company's stock symbol AHCO.
Form 144 ADAPTHEALTH CORP. For: 12 November By Investing.com
This article announces the filing of Form 144 for ADAPTHEALTH CORP. on November 12. Form 144 is a notice filed with the SEC by an insider of a company intending to sell restricted or control securities. The brief notice indicates that ADAPTHEALTH CORP. (AHCO) is the subject of this filing.
AdaptHealth (AHCO) Shares Just Moved, What Is Behind The Latest Attention?
AdaptHealth (AHCO) has seen recent investor attention after reporting a third-quarter goodwill impairment, raising its 2026 revenue guidance, and posting new quarterly results. The company's shares have rebounded significantly over the past 30 and 90 days despite a year-to-date decline, with investors now evaluating whether the increased revenue guidance and progress on capitated contracts outweigh concerns about the goodwill hit and ongoing losses. Simply Wall St's analysis suggests AdaptHealth is currently 11% undervalued.
AdaptHealth Corp. Stock 12‑Month Price Target Raised to $8.86, Implies 41% Upside
AdaptHealth Corp. (AHCO) has seen its average 12-month price target raised to $8.86 by analysts, up from $8.71. This new target implies a potential upside of approximately 41% based on the Nov. 3 closing price, with individual forecasts ranging from $8 to $10 per share. The consensus rating from 7 covering analysts remains a "Buy."
AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to know
Shares of AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS surged after election results confirmed Democrats reclaimed majorities in Congress, easing regulatory uncertainty around drug pricing policy. Wall Street analysts project a stronger recovery for the biopharmaceutical sector as existing government policies are expected to remain intact without unexpected new restrictions. This shift is viewed as a stabilizing dynamic, with congressional checks and balances moderating executive policy decisions and supporting investments in the pharmaceutical and biotechnology sectors.
AdaptHealth Corp (AHCO) (Q3 2026) Earnings Call Highlights: Revenue Beat and Capitated Contract ...
AdaptHealth Corp (AHCO) exceeded its Q3 2026 guidance, reporting a net revenue of $745.6 million and adjusted EBITDA of $141.9 million. The company's largest capitated contract became profitable, contributing significantly to organic growth and showing a positive margin trajectory. Despite a GAAP net loss due to a goodwill impairment charge and lowered full-year free cash flow guidance, AdaptHealth demonstrated cost discipline through headcount reduction and secured new agreements, while navigating uncertainties like the Medline bed field action.
AdaptHealth Q3 2026 Earnings Call Transcript
AdaptHealth (NASDAQ: AHCO) reported strong third-quarter 2026 financial results, with net revenue up 10.9% year-over-year to $745.6 million and adjusted EBITDA of $141.9 million, exceeding guidance. The company saw significant improvements in its largest capitated contract and is actively managing the sale of its Diabetes Health business and the Medline bed recall. AdaptHealth raised its full-year revenue and adjusted EBITDA guidance, emphasizing a focus on sleep, respiratory, and wellness-at-home services for predictable, sustainable growth.
Revenue rises 10.9%, but AdaptHealth (AHCO) cuts its 2026 free cash flow outlook.
AdaptHealth (AHCO) reported a 10.9% increase in third-quarter 2026 net revenue to $745.6 million, with 12.8% organic growth. However, the company lowered its fiscal 2026 free cash flow guidance to $50 million–$75 million from $80 million–$120 million, primarily due to a pre-tax goodwill impairment of $184.8 million which contributed to a net loss. AdaptHealth is also progressing with the sale of its Diabetes Health business for $235.0 million in cash, expected to close in early 2027.
AdaptHealth (NASDAQ:AHCO) surprises with Q3 2026 sales, stock soars
AdaptHealth Corp. (NASDAQ:AHCO) reported Q3 2026 results that exceeded market revenue expectations, with sales of $745.6 million, though revenue declined 9.1% year-on-year. The company's GAAP loss of $1.13 per share significantly missed analyst estimates, but adjusted EBITDA and full-year guidance were above consensus. Shares surged 9.6% following the mixed results, as the company focuses on Sleep Health, Respiratory Health, and Wellness-at-Home.
AdaptHealth (NASDAQ:AHCO) surprises with Q3 2026 sales, stock soars
AdaptHealth (NASDAQ:AHCO) reported mixed Q3 2026 results, with revenue exceeding expectations at $745.6 million despite a 9.1% year-on-year decline. The company also raised its full-year revenue and EBITDA guidance, though its GAAP loss of $1.13 per share significantly missed analyst estimates. Following the announcement, shares of AdaptHealth surged by 9.6%.
AdaptHealth Corp. (AHCO) Misses Q3 EPS by 120c ; Offers Guidance
AdaptHealth Corp. (AHCO) reported a significant miss in its Q3 EPS, coming in at ($1.23) against an analyst estimate of ($0.03), a difference of $1.20. Despite the EPS miss, the company's revenue of $745.6 million surpassed the consensus estimate of $725.98 million. AdaptHealth also provided FY2026 revenue guidance between $2.88 billion and $2.9 billion, which is slightly above the consensus of $2.87 billion.
AdaptHealth (NASDAQ:AHCO) surprises with Q3 2026 sales, stock soars
AdaptHealth Corp. (NASDAQ: AHCO) reported mixed Q3 2026 results, exceeding revenue and Adjusted EBITDA expectations but missing significantly on GAAP EPS. Despite a 9.1% year-on-year revenue decline, the company raised its full-year revenue and EBITDA guidance, leading to a 9.6% surge in its stock immediately after the announcement. CEO Suzanne Foster highlighted strong organic revenue growth and progress in selling its Diabetes Health business to focus on Sleep Health, Respiratory Health, and Wellness-at-Home.
AdaptHealth (NASDAQ:AHCO) surprises with Q3 2026 sales, stock soars
AdaptHealth Corp. (NASDAQ:AHCO) reported Q3 2026 results that exceeded revenue expectations, with sales of $745.6 million, though revenue was down 9.1% year-on-year. The company provided full-year revenue guidance of approximately $2.89 billion and adjusted EBITDA guidance of $517.5 million, both near or above analyst consensus. Despite a significant GAAP loss per share of $1.13, shares surged 9.6% immediately after the results due to strong organic revenue growth and better-than-expected EBITDA.
AdaptHealth (AHCO) reports earnings tomorrow: what to expect
AdaptHealth (AHCO) is set to report its earnings before market hours on Tuesday. Analysts anticipate an 11.5% year-on-year revenue decline, a significant reversal from the previous year's increase, and the company has missed Wall Street's revenue estimates multiple times in the past two years. Investors will be watching closely, especially given that some peers in the healthcare providers & services segment have already reported strong Q3 results.
AdaptHealth Corp. (AHCO) Seasonal returns chart
The article provides a seasonal returns chart for AdaptHealth Corp. (AHCO), showing average monthly price returns from 2018 to 2026. It also includes current stock data, an upcoming Q3 2026 earnings call announcement, and related tickers.
AdaptHealth Sets November 3 Earnings Review for Investors
AdaptHealth Corp. (Nasdaq: AHCO) is scheduled to report its third-quarter 2026 financial results before U.S. markets open on November 3. The company will host a conference call at 8:30 a.m. Eastern Time to discuss its performance and business activities, with a webcast and replay available on its investor relations website. AdaptHealth provides home medical equipment and healthcare services across four segments to approximately 4.3 million patients annually.
North Carolina customers may qualify for a cash payment from the AdaptHealth class action settlement!
North Carolina residents who purchased, leased, or rented medical equipment from AdaptHealth between April 3, 2019, and March 31, 2026, may be eligible for a cash payment from a $14.31 million class action settlement. The lawsuit alleges AdaptHealth engaged in improper debt collection practices, including billing for unreceived or returned equipment and sending misleading collection letters. Depending on the class they fall into, eligible customers could receive $47 or $3,500.
AHCO Q3'26 Earnings: revenue estimate is 725.87M USD
AdaptHealth Corp. (AHCO) is projected to report its Q3'26 financial results on November 3, with an estimated revenue of $725.87 million and an anticipated EPS of ($0.05). The company's previous quarterly performance shows fluctuating revenue and EPS surprises.
AdaptHealth Corp. Estimates – NASDAQ:AHCO
This page on TradingView provides financial data and analyst estimates for AdaptHealth Corp. (NASDAQ: AHCO). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics, as well as visualize trends over time. The platform also offers disclaimers regarding investment advice.
AdaptHealth Corp. (AHCO) Stock forecasts
Argus has lowered its target price for AdaptHealth Corp. (AHCO) to $5.00, citing the company's engagement in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. The current price of AHCO stock is $5.99.
Home medical equipment provider AdaptHealth will discuss results live Nov. 3 at 8:30 a.m. ET.
AdaptHealth Corp. (AHCO) will release its third-quarter 2026 financial results before the market opens on November 3, 2026. The company will host a teleconference at 8:30 a.m. ET to discuss these results and business activities with analysts and investors. A replay of the call will be available on AdaptHealth's website under "Investor Relations" for six months.
AdaptHealth Corp. (AHCO) Stock Forecasts
Argus has raised its target price for AdaptHealth Corp. (AHCO) to $6.00. The company provides patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies, and related services. The current stock price for AHCO is $6.02.
AdaptHealth Corp. (AHCO) Stock forecasts
Argus has updated its forecast for AdaptHealth Corp. (AHCO), raising its target price to $6.00. The company provides patient-centered, healthcare-at-home solutions, including home medical equipment and related services. The current stock price for AHCO is $5.75.
AHCO: AdaptHealth Corp Latest Stock Price, Analysis, News and Trading Ideas
This article provides a detailed overview of AdaptHealth Corp (AHCO), including its current stock price, market capitalization, key financial metrics, and upcoming earnings date. It also highlights the company's business activities in home healthcare equipment and services, alongside recent news and investor sentiment.
AdaptHealth Corp. (AHCO) Options Chain
This article provides the options chain data for AdaptHealth Corp. (AHCO) as of October 15, 2026. It indicates that there are currently no calls or puts listed for various strike prices, with options data delayed by 15 minutes. The stock closed at $6.39, up 2.24%.
DIMENSIONAL FUND ADVISORS LP Trims AdaptHealth Corp (AHCO) Stake
Dimensional Fund Advisors LP reduced its stake in AdaptHealth Corp (AHCO) by selling 1,275,223 shares at $5.64 on September 30, 2026. Despite the reduction, AHCO still accounts for 0.01% of the firm's portfolio, and the stock is considered 33% undervalued according to its GF Value. AdaptHealth Corp, a provider of home medical equipment, faces financial health challenges, including low growth and momentum ranks, despite its apparent undervaluation.
Understanding Momentum Shifts in (AHCO)
This article analyzes Adapthealth Corp. (NASDAQ: AHCO), highlighting a potential shift from positive near-term sentiment amidst broader weak alignment. It details an exceptional risk-reward setup targeting a 37.5% gain and outlines three AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term outlooks.
AdaptHealth Corp. (AHCO) Stock Forecasts
AdaptHealth Corp. (AHCO) is a company that provides patient-centered, healthcare-at-home solutions. An Argus report from October 7, 2026, discusses AHCO's performance, indicating a current stock price of $6.06. The report offers detailed analysis and insights for investors.
(AHCO) Movement as an Input in Quant Signal Sets
The article analyzes Adapthealth Corp. (NASDAQ: AHCO) using AI models, indicating weak sentiment across all time horizons which supports a short bias. It provides specific trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis detailing support and resistance levels. The report highlights elevated downside risk and the absence of additional long-term support signals for AHCO.
AdaptHealth Corp. (AHCO) Stock Forecasts
The article "AdaptHealth Corp. (AHCO) Stock Forecasts" was found on Yahoo Finance. However, the core content regarding the stock forecasts is missing or an error occurred during retrieval. The page primarily displays navigation elements, market data for various indices and currencies, and standard website disclaimers rather than specific information about AHCO.
AdaptHealth Class Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against AdaptHealth Corp. (NASDAQ: AHCO) and reminds investors of the September 27, 2021 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that AdaptHealth misrepresented its organic growth trajectory by retroactively inflating past numbers without disclosure, thus materially overstating its financial prospects. Investors who suffered losses exceeding $50,000 between November 11, 2019, and July 16, 2021, are encouraged to contact the firm.
AdaptHealth Names Currie CFO as Growth Push Takes Shape
AdaptHealth Corp. has appointed Harriss T. Currie as its new Chief Financial Officer, succeeding Jason Clemens. Currie, a seasoned healthcare executive, will be responsible for the company's financial organization as it aims for significant revenue and EBITDA growth. This appointment is expected to help AdaptHealth translate its strategic contracts into earnings.
AdaptHealth at Jefferies conference: focus shifts to scale and capitation
AdaptHealth discussed its business transformation at the Jefferies Healthcare Services and Technology Conference, shifting from an acquisition-led model to a focused approach on sleep health, respiratory care, and home medical equipment. The company highlighted new challenges such as a manufacturing price change and a difficult Kaiser Permanente contract rollout, alongside benefits from portfolio cleanup and national scale. AdaptHealth aims to become a preferred national provider by leveraging technology, strategic partnerships, and focusing on organic growth in its core segments, expecting mid-single-digit growth in sleep health.
Currie Harriss T Awarded 141,372 Shares of AdaptHealth Corp, Establishing New Insider Stake
Currie Harriss T, CFO of AdaptHealth Corp. (NASDAQ:AHCO), was granted 141,372 shares on September 9, 2026, establishing a new insider position. This transaction, filed under SEC transaction code A, represents 100% of Harriss’s total AdaptHealth shareholding. Following this award, Harriss now holds 141,372 shares in the company.
AdaptHealth To Participate in Upcoming Investor Conferences
AdaptHealth Corp. (NASDAQ: AHCO) announced its participation in three upcoming investor conferences: the 2026 Jefferies Healthcare Services and Technology Conference on September 14, the Baird 2026 Global Healthcare Conference on September 15, and the Deutsche Bank 2026 Healthcare Summit on September 17, 2026. Key executives including CEO Suzanne Foster and CFO Harriss Currie will represent the company, which is a national leader in healthcare-at-home solutions.
Truist reiterates Buy on AdaptHealth stock after CFO change
Truist Securities reiterated a Buy rating and $9.00 price target for AdaptHealth (NASDAQ:AHCO) following the appointment of Harriss Currie as the new CFO. The stock has seen a significant year-to-date decline due to operational challenges, including disappointing Q2 results and a guidance cut. Despite these issues, Truist is encouraged by organic revenue growth trends and a recent Diabetes business divestiture, viewing the stock as a "show me story" where execution will be key for recovery.
People on the Move: Harriss Currie Named Chief Financial Officer of AdaptHealth
AdaptHealth Corp. has appointed Harriss T. Currie as its new Chief Financial Officer, effective September 9, 2026. Currie brings extensive financial leadership experience from various healthcare and medical technology companies, succeeding Jason Clemens. CEO Suzanne Foster welcomed Currie, highlighting his expected contributions to the company's growth.
Why AdaptHealth (AHCO) Stock Is Down Today
AdaptHealth (AHCO) stock dropped by 8.6% after the company announced a change in its Chief Financial Officer position. Harriss T. Currie was appointed CFO, replacing Jason Clemens, which triggered investor caution regarding operational continuity. This follows a significant 39.5% drop a month prior due to disappointing Q2 results and reduced 2026 financial guidance.
AdaptHealth (AHCO) taps new CFO with $670,000 salary
AdaptHealth Corp. (AHCO) has announced the appointment of Harriss Currie as its new Chief Financial Officer, effective September 9, 2026. Currie will receive an annual base salary of $670,000, a target annual bonus of 100% of his base salary, and restricted stock units valued at $818,462. He succeeds Jason Clemens, who will assist with the transition until October 1, 2026.
AdaptHealth Appoints Harriss Currie as Chief Financial Officer
AdaptHealth Corp. has announced the appointment of Harriss T. Currie as its new Chief Financial Officer, effective September 9, 2026. Mr. Currie brings extensive experience from previous CFO roles at Luminex Corp, Health Track Rx, and Impulse Dynamics, as well as serving as President of the Regenerative Medicine division of 3D Systems. He will succeed Jason Clemens, who will assist with the transition until October 1, 2026.
Adapthealth Stock Price Forecast. Should You Buy AHCO?
AdaptHealth Corp. (AHCO) is currently rated as a Sell Candidate by StockInvest.us with a technical score of -4.97. The stock price fell by 3.45% on the last trading day, and a significant further fall of 35.77% is forecast for the next three months. Investors are advised against buying AHCO due to negative signals and a falling trend.
Bronstein, Gewirtz & Grossman, LLC Encourages AdaptHealth Corp. (AHCO) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AdaptHealth Corp. (AHCO) after the company reported significantly lower-than-expected Q2 revenue, a GAAP loss, and a substantial reduction in full-year guidance. Shareholders who purchased AdaptHealth securities are encouraged to contact the firm to assist with the investigation. The investigation stems from a 26% share drop following the disappointing financial results.
Bronstein, Gewirtz & Grossman, LLC Is Investigating AdaptHealth Corp. (AHCO) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AdaptHealth Corp. (NASDAQ: AHCO) after the company reported disappointing second-quarter results and significantly reduced its full-year guidance. AdaptHealth's shares fell by as much as 26% following the announcement of lower-than-expected revenue, a GAAP loss with a goodwill impairment charge, and a substantial cut to its 2026 outlook. The firm encourages affected AdaptHealth investors to contact them for more information or to assist with the investigation.
AdaptHealth Breach Exposed Health Records of One in 13 Vermonters
A data breach at AdaptHealth, a durable medical equipment provider, exposed the health records of 48,090 Vermonters, representing about one in 13 residents. This incident accounts for 57% of all Vermonters affected by data breaches reported to the state Attorney General's Office since April 2026. The breach, attributed to social engineering targeting a third-party contractor's account, allowed access to patient management systems and electronic health record portals.
AdaptHealth breach exposed health records of one in 13 Vermonters
A data breach at AdaptHealth, a durable medical equipment provider, exposed the health records of 48,090 Vermonters, affecting about one in every 13 residents. This incident accounts for 57% of all data breaches reported to the Vermont Attorney General's Office since April 2026. The breach, attributed to social engineering rather than a hack, involved a compromised third-party contractor's account, leading to the exfiltration of patient data by the criminal group ShinyHunters.
AdaptHealth Corp. (NASDAQ:AHCO) Given Average Recommendation of "Moderate Buy" by Brokerages
AdaptHealth Corp. (NASDAQ:AHCO) has received an average rating of "Moderate Buy" from analysts, despite a significant quarterly earnings miss where the company reported an adjusted loss of $0.99 per share against an expected $0.17 earnings. The stock is currently trading near its 52-week low. Insider activity shows a director recently increased their stake, while institutional investors hold a substantial portion of the company's shares.